It has been about a month since the last earnings report for Axsome Therapeutics (AXSM). Shares have lost about 0.8% in that time frame, outperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Axsome due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
VGM Scores
At this time, Axsome has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Axsome has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Axsome belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Biogen Inc. (BIIB), has gained 3.5% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.
Biogen reported revenues of $2.45 billion in the last reported quarter, representing a year-over-year change of +2.9%. EPS of $3.44 for the same period compares with $2.95 a year ago.
For the current quarter, Biogen is expected to post earnings of $3.59 per share, indicating a change of -2.2% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.5% over the last 30 days.
Biogen has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report
Biogen Inc. (BIIB) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Down%200.8%25%20Since%20Last%20Earnings%20Report%3A%20Can%20It%20Rebound%3F%20%7C%20Nasdaq&_biz_n=12&rnd=91865&cdn_o=a&_biz_z=1743103620213)
%20Down%200.8%25%20Since%20Last%20Earnings%20Report%3A%20Can%20It%20Rebound%3F%20%7C%20Nasdaq&rnd=334952&cdn_o=a&_biz_z=1743103620219)